research Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.
Search
for
Sort by
Research
960-990 / 1000+ results 
research Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
research Recombinant Human Annexin A5 Ameliorates Localized Scleroderma by Inhibiting the Activation of Fibroblasts and Macrophages
Recombinant Human Annexin A5 may help treat localized scleroderma by reducing skin thickening and inflammation.
research Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
research 710 Use of mass spectrometry imaging and a full thickness 3D skin equivalent for evaluation of percutaneous absorption
The document concludes that various topical treatments show promise for skin conditions like atopic dermatitis, psoriasis, and hair loss.
research Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy
Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
research Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
research Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
Skin side effects from melanoma immunotherapy are common and may indicate better survival.
research Resolution of refractory systemic lupus erythematosus-associated alopecia with anifrolumab: a case report
research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
research 42175 PASI improvement in the first 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE guselkumab clinical trials
Guselkumab significantly improves psoriasis symptoms within 12 weeks.
research Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
research Drug-induced alopecia after dupilumab therapy
Dupilumab may cause significant hair loss, which can reverse after stopping the drug.
research Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
research ANIFROLUMAB IN THE MANAGEMENT OF LUPUS HEADACHES: A CASE REPORT
Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.
research Non-scarring Alopecia in Pemphigus Foliaceus
Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.
research TREM2 macrophages induced by human lipids drive inflammation in acne lesions
TREM2 macrophages and unsaturated lipids contribute to acne inflammation.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
research Alopecia Areata Associated with Dupilumab: National Database Study
Dupilumab users have a higher risk of developing alopecia areata.
research Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
Blocking EGFR in skin cells doesn't majorly increase inflammation markers.
research Revolutionizing psoriasis care: Microneedle innovations in treatment and diagnosis
Microneedles offer a promising, less invasive way to treat and monitor psoriasis.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Efficacy and safety of systemic monotherapy in the management of generalized pustular psoriasis: A systematic review
Different treatments for skin conditions were found to be effective and generally safe, with biologics recommended as the first choice for generalized pustular psoriasis.
research Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
Ritlecitinib is cost-effective for severe alopecia areata in Japan.
research Potencial de nanopartículas poliméricas de Delonix contendo isotretinoína para o tratamento da acne
Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.
research JAK inhibitors for the treatment of alopecia areata
JAK inhibitors show promise in treating moderate to severe alopecia areata.
research Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study
research Systemic Therapies for Scarring and Non-scarring Alopecia
JAK inhibitors are effective for hair regrowth in severe alopecia areata.